Biopep Solutions Inc. is a privately owned, development-stage biotechnology company that discovers and develops innovative therapeutic products for the treatment of cancers and other diseases. The Company’s lead product, BPS-001, is a heterogeneous biologic extract containing a known composition of multiple peptide and protein components. BPS-001 is produced from Leech Saliva Extract using patented extraction processes and proprietary technology. The objective of the Company is to develop the use of BPS-001 over the next three years to treat several forms of cancers.
Currently, Biopep is actively pursuing clinical trials for the use of BPS-001 as a treatment for metastatic, castration resistant prostate cancer (mCRPC).
Pre-clinical pharmacological studies and the preliminary Chemistry, Manufacturing and Control (CMC) specifications have been completed and we anticipate earning approval of an Investigational New Drug Application (IND) from the US, FDA and a Clinical Trial Application (CTA) from Health Canada to proceed with phase 1/2 clinical testing.
The chemical characterization and preclinical studies suggest that BPS-001 contains multiple active components eliciting activities that interfere with carcinogenesis by: inhibiting angiogenesis, increasing apoptosis of cancer cells; and, by exhibiting anti-inflammatory properties. Thus, unlike currently approved molecularly targeted agents, BPS-001 has multivalent mechanisms that act by blocking more than one target that contributes to carcinogenesis.